Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AZD7295 dose-ranging study with pegylated interferon alfa-2a and ribavirin in chronic hepatitis C genotype 1b
2010-018361-33Phase 2Completed
- Sponsor
- Arrow Therapeutics
- Start
- Jun 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in hepatitis C virus infection comparing AZD7295 + standard of care with Placebo + standard of care (2 arms). Primary endpoint: Rapid virologic response. Started Jun 2010; status: completed.
02
Drugs
AZD-7295
03
Conditions
hepatitis C virus infection
Beyond the preview
Go deeper on 2010-018361-33.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-018361-33.